Advances in medical revascularisation treatments in acute ischemic stroke

Thrombosis

Volumn 2014, Issue , 2014, Pages

  Asadi, H ^a   Yan, B ^a   Dowling, R ^a   Wong, S ^b   Mitchell, P ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WESTERN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANCROD; ARGATROBAN; DESMOTEPLASE; ECHO CONTRAST MEDIUM; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; TENECTEPLASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ADJUVANT THERAPY; BRAIN ISCHEMIA; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; PRIORITY JOURNAL; RECANALIZATION; REVIEW; SONOTHROMBOLYSIS; STROKE PATIENT; THERAPY;

EID: 84949458451     PISSN: 20901488     EISSN: 20901496     Source Type: Journal    
DOI: 10.1155/2014/714218     Document Type: Review

References (71)

1. A. S. Ferrell and G. W. Britz, "Developments on the horizon in the treatment of neurovascular problems," Surgical Neurology International, vol. 4, supplement 1, pp. S31-S37, 2013.
2. K. A. Blackham, P. M. Meyers, T. A. Abruzzo et al., "Endovascular therapy of acute ischemic stroke: report of the standards of practice committee of the society of neuroInterventional surgery," Journal of NeuroInterventional Surgery, vol. 4, no. 2, pp. 87-93, 2012.
3. D. Lloyd-Jones, R. Adams, M. Carnethon et al., "Heart disease and stroke statistics-2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee," Circulation, vol. 119, no. 3, pp. 480-486, 2009.
4. W. Hacke, A. J. Furlan, Y. Al-Rawi et al., "Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebocontrolled study,"TheLancetNeurology, vol. 8, no. 2,pp. 141-150, 2009.
5. S. M. Adelman, "The national survey of stroke. Economic impact," Stroke, vol. 12, supplement 1, no. 2, pp. I-69-I-87, 1981.
6. T. N. Taylor,P. H. Davis, J. C. Torner, J. Holmes, J. W. Meyer, and M. F. Jacobson, "Lifetime cost of stroke in the United States," Stroke, vol. 27, no. 9, pp. 1459-1466, 1996.
7. W. Rosamond, K. Flegal, G. Friday et al., "Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee," Circulation, vol. 115, no. 5, pp. e69-e171, 2007.
8. R. G. González, W. A. Copen, P. W. Schaefer et al., "The Massachusetts General Hospital acute stroke imaging algorithm: an experience and evidence based approach," Journal of NeuroInterventional Surgery, vol. 5, supplement 1, pp. i7-i12, 2013.
9. J.-H. Rha and J. L. Saver, "The impact of recanalization on ischemic stroke outcome: a meta-analysis," Stroke, vol. 38, no. 3, pp. 967-973, 2007.
10. A. Meretoja,M. Keshtkaran, J. L. Saver et al., "Stroke thrombolysis: save a minute, save a day," Stroke, vol. 45, no. 4, pp. 1053-1058, 2014.
11. A. Eissa, I. Krass, C. Levi, J. Sturm, R. Ibrahim, and B. Bajorek, "Understanding the reasons behind the low utilisation of thrombolysis in stroke," Australasian Medical Journal, vol. 6, no. 3, pp. 152-163, 2013.
12. K. R. Lees, E. Bluhmki, R. von Kummer et al., "Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials," The Lancet, vol. 375, no. 9727, pp. 1695-1703, 2010.
13. M. Ebinger, B. Winter, M. Wendt et al., "Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial," Journal of the AmericanMedical Association, vol. 311, no. 16, pp. 1622-1631, 2014.
14. A. J. Furlan, D. Eyding, G. W. Albers et al., "Dose escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset," Stroke, vol. 37, no. 5, pp. 1227-1231, 2006.
15. H. P. Adams Jr., G. del Zoppo, M. J. Alberts et al., "Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists," Circulation, vol. 115, no. 20, pp. e478-534, 2007.
16. "Tissue plasminogen activator for acute ischemic stroke," New England Journal ofMedicine, vol. 333, no. 24, pp. 1581-1587, 1995.
17. W. Hacke, M. Kaste, E. Bluhmki et al., "Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke," The New England Journal ofMedicine, vol. 359, no. 13, pp. 1317-1329, 2008.
18. P. Sandercock, J. M. Wardlaw, R. I. Lindley et al., "The benefits and harms of intravenous thrombolysiswith recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial," The Lancet, vol. 379, no. 9834, pp. 2352-2363, 2012.
19. N. Ahmed, L. Kellert, K. R. Lees, R. Mikulik, T. Tatlisumak, and D. Toni, "Results of intravenous thrombolysis within 4. 5 to6hours and updatedresults within 3 to 4. 5 hours of onset ofacute ischemic strokerecorded in the safe implementation of treatment in stroke international stroke thrombolysis register (SITS-ISTR): an observational study," JAMA Neurology, vol. 70, no. 7, pp. 837-844, 2013.
20. S. M. Zinkstok and Y. B. Roos, "Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial," The Lancet, vol. 380, no. 9843, pp. 731-737, 2012.
21. M. Parsons, N. Spratt, A. Bivard et al., "A randomized trial of tenecteplase versus alteplase for acute ischemic stroke,"TheNew England Journal ofMedicine, vol. 366, no. 12, pp. 1099-1107, 2012.
22. W. Hacke, G. Albers, Y. Al-Rawi et al., "The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase," Stroke, vol. 36, no. 1, pp. 66-73, 2005.
23. D. G. Sherman, R. P. Atkinson, T. Chippendale et al., "Intravenous ancrod for treatment of acute ischemic stroke. the STAT study: a randomized controlled trial," Journal of the American Medical Association, vol. 283, no. 18, pp. 2395-2403, 2000.
24. M. Siebler, M. G. Hennerici, D. Schneider et al., "Safety of tirofiban in acute ischemic stroke: the SaTIS trial," Stroke, vol. 42, no. 9, pp. 2388-2392, 2011.
25. H. P. Adams Jr., M. B. Effron, J. Torner et al., "Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTTII)," Stroke, vol. 39, no. 1, pp. 87-99, 2008.
26. A. M. Pancioli, O. Adeoye, P. A. Schmit et al., "Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial," Stroke, vol. 44, no. 9, pp. 2381-2387, 2013.
27. M. P. LaMonte, M. L. Nash, D. Z. Wang et al., "Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study," Stroke, vol. 35, no. 7, pp. 1677-1682, 2004.
28. A. D. Barreto, A. V. Alexandrov, P. Lyden et al., "The Argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study," Stroke, vol. 43, no. 3, pp. 770-775, 2012.
29. M. G. Lansberg, M. Straka, S. Kemp et al., "MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study,"The Lancet Neurology, vol. 11,no. 10, pp. 860-867, 2012.
30. G. W. Albers,V. N. Thijs, L. Wechsler et al., "Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study," Annals of Neurology, vol. 60, no. 5, pp. 508-517, 2006.
31. S. M. Davis, G. A. Donnan, M. W. Parsons et al., "Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial," The Lancet Neurology, vol. 7, no. 4, pp. 299-309, 2008.
32. A. V. Alexandrov, C. A. Molina, J. C. Grotta et al., "Ultrasoundenhanced systemic thrombolysis for acute ischemic stroke," The New England Journal ofMedicine, vol. 351, no. 21, pp. 2170-2178, 2004.
33. C. A. Molina, A. D. Barreto, G. Tsivgoulis et al., "Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial," Annals of Neurology, vol. 66, no. 1, pp. 28-38, 2009.
34. G. J. del Zoppo, J. L. Saver, E. C. Jauch, and H. P. Adams Jr., "Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American heart association/american stroke association," Stroke, vol. 40, no. 8, pp. 2945-2948, 2009.
35. G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal, "Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and ThrombolyticTherapy," Chest, vol. 126, supplement 3, pp. 483S-512S, 2004.
36. C. A. Molina and J. L. Saver, "Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies," Stroke, vol. 36, no. 10, pp. 2311-2320, 2005.
37. A. D. Barreto and A. V. Alexandrov, "Adjunctive and alternative approaches to current reperfusion therapy," Stroke, vol. 43, no. 2, pp. 591-598, 2012.
38. R. Mikulík, M. Dufek, D. Goldemund, and M. Reif, "A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke," European Journal of Neurology, vol. 13, no. 10, pp. 1106-1111, 2006.
39. S. M. Zinkstok, M. Vermeulen, J. Stam, R. J. de Haan, and Y. B. Roos, "A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial," Trials, vol. 11, article 51, 2010.
40. G. J. del Zoppo, R. T. Higashida, A. J. Furlan,M. S. Pessin, H. A. Rowley, and M. Gent, "PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke," Stroke, vol. 29, no. 1, pp. 4-11, 1998.
41. A. Furlan, R. Higashida, L. Wechsler et al., "Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial," Journal of the American Medical Association, vol. 282, no. 21, pp. 2003-2011, 1999.
42. M. Yepes, B. D. Roussel, C. Ali, and D. Vivien, "Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic," Trends in Neurosciences, vol. 32, no. 1, pp. 48-55, 2009.
43. E. C. Haley, J. L. P. Thompson, J. C. Grotta et al., "Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial," Stroke, vol. 41, no. 4, pp. 707-711, 2010.
44. E. C. Haley Jr., P. D. Lyden, K. C. Johnston, and T. M. Hemmen, "A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke," Stroke, vol. 36, no. 3, pp. 607-612, 2005.
45. D. Smadja, N. Chausson, J. Joux et al., "A new therapeutic strategy for acute ischemic stroke: sequential combined intravenous tpa-tenecteplase for proximal middle cerebral artery occlusion based on first results in 13 consecutive patients," Stroke, vol. 42, no. 6, pp. 1644-1647, 2011.
46. N. Logallo, C. E. Kvistad, A. Nacu et al., "The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke," BMC Neurology, vol. 14, no. 1, article 106, 2014.
47. R. von Kummer, G. W. Albers, E. Mori et al., "The desmoteplase in acute ischemic stroke (DIAS) clinical trial program," International Journal of Stroke, vol. 7, no. 7, pp. 589-596, 2012.
48. J. F. Kirmani, A. Alkawi, S. Panezai, and M. Gizzi, "Advances in thrombolytics for treatment of acute ischemic stroke," Neurology, vol. 79, no. 13, supplement 1, pp. S119-S125, 2012.
49. D. E. Levy, G. J. Del Zoppo, B. M. Demaerschalk et al., "Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program," Stroke, vol. 40, no. 12, pp. 3796-3803, 2009.
50. M. G. Hennerici, R. Kay, J. Bogousslavsky, G. L. Lenzi, M. Verstraete, and J. M. Orgogozo, "Intravenous ancrod for acute ischaemic stroke in the European stroke treatment with ancrod trial: a randomised controlled trial," The Lancet, vol. 368, no. 9550, pp. 1871-1878, 2006.
51. M. G. Hennerici, R. Kay, J. Bogousslavsky, G. L. Lenzi, M. Verstraete, and J. M. Orgogozo, "Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial," The Lancet, vol. 368, no. 9550, pp. 1871-1878, 2006.
52. P. R. Eisenberg, B. E. Sobel, and A. S. Jaffe, "Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator," Journal of the American College of Cardiology, vol. 19, no. 5, pp. 1065-1069, 1992.
53. H. Pereira, "Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTOVrandomised trial,"RevistaPortuguesa deCardiologia, vol. 20, no. 6, pp. 687-688, 2001.
54. E. M. Ohman, N. S. Kleiman, G. Gacioch et al., "Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: results of a randomized, placebocontrolled, dose-ranging trial," Circulation, vol. 95, no. 4, pp. 846-854, 1997.
55. G. Torgano, B. Zecca, V. Monzani et al., "Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a doubleblind randomized trial," Cerebrovascular Diseases, vol. 29, no. 3, pp. 275-281, 2010.
56. I. K. Jang, D. F. M. Brown, R. P. Giugliano et al., "Amulticenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study," Journal of the American College of Cardiology, vol. 33, no. 7, pp. 1879-1885, 1999.
57. H. Kawai, K. Umemura, and M. Nakashima, "Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model," Japanese Journal of Pharmacology, vol. 69, no. 2, pp. 143-148, 1995.
58. D. C. Morris, L. Zhang, Z. G. Zhang et al., "Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke," Stroke, vol. 32, no. 11, pp. 2635-2640, 2001.
59. R. M. Sugg, J. K. Pary, K. Uchino et al., "Argatroban tPA stroke study: study design and results in the first treated cohort," Archives of Neurology, vol. 63, no. 8, pp. 1057-1062, 2006.
60. A. D. Barreto, "Randomized controlled trial of argatroban with tPA for acute stroke (ARTSS-2)," in ClinicalTrials. gov, National Library of Medicine (US), Bethesda, Md, USA, 2011, https://clinicaltrials. gov/show/NCT01464788.
61. G. J. del Zoppo, K. Poeck, M. S. Pessin et al., "Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke," Annals of Neurology, vol. 32, no. 1, pp. 78-86, 1992.
62. M. Saqqur, K. Uchino, A. M. Demchuk et al., "Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke," Stroke, vol. 38, no. 3, pp. 948-954, 2007.
63. C. A. Molina, J. Montaner, J. F. Arenillas, M. Ribo,M. Rubiera, and J. Alvarez-Sabín, "Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes," Stroke, vol. 35, no. 2, pp. 486-490, 2004.
64. C. H. Riedel, P. Zimmermann, U. Jensen-Kondering, R. Stingele, G. Deuschl, and O. Jansen, "The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length," Stroke, vol. 42,no. 6, pp. 1775-1777, 2011.
65. M. Rubiera, J. Alvarez-Sabín, M. Ribo et al., "Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke," Stroke, vol. 36,no. 7, pp. 1452-1456, 2005.
66. H. Ma, M. W. Parsons, S. Christensen et al., "A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND)," International Journal of Stroke, vol. 7, no. 1, pp. 74-80, 2012.
67. G. Thomalla, "Efficacy and safety of MRI-based thrombolysis in wake-up stroke (WAKE-UP)," in ClinicalTrials. gov [Internet], National Library of Medicine (US), Bethesda, Md, USA, 2014, NLM Identifier: NCT01525290, http://clinicaltrials. gov/show/NCT01525290.
68. J. A. Álvarez-Fernández, "Ultrasound-enhanced systemic thrombolysis. An effective and underutilized treatment for acute ischemic stroke," Medicina Intensiva, vol. 35, no. 2, pp. 134-135, 2011.
69. M. Daffertshofer, A. Gass, P. Ringleb et al., "Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: Increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial," Stroke, vol. 36, no. 7, pp. 1441-1446, 2005.
70. "Cerevast. Phase 3, randomized, placebo-controlled, doubleblinded trial of the combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator (tPA) for emergent revascularization in acute ischemic stroke (CLOTBUSTER)," in ClinicalTrials. gov, National Library of Medicine (US), Bethesda, Md, USA, 2014, http://clinicaltrials. gov/show/NCT01098981.
71. C. A. Molina, M. Ribo, M. Rubiera et al., "Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator," Stroke, vol. 37, no. 2, pp. 425-429, 2006.